New Medicines Australia Chair critical to HTA reforms

Former MTPConnect Chair, Sue MacLeman, is taking the reins as Chair of Medicines Australia, bringing three decades of firepower in pharmaceuticals, biotech, and medtech.

A force in the life sciences sector, MacLeman has led ASX, AIM, and NASDAQ-listed healthtech companies, navigated boardrooms across public and private enterprises, and shaped national policy through academic and government advisory roles.

“I am honoured to be appointed as Chair of Medicines Australia and I look forward to working with the Medicines Australia Board and Executive to continue championing the latest advancements in medicine, and advocating for patients to have fast, universal access to new treatments,” MacLeman said.

Her credentials pack a serious punch – Bachelor of Pharmacy from the University of Queensland, Master of Laws from Deakin University, and Master of Marketing from Melbourne Business School. She also serves on the NSW Government Innovation and Productivity Council and is a Fellow of both the Australian Academy of Technology and Engineering and the Australian Institute of Company Directors.

Medicines Australia CEO Liz de Somer welcomed MacLeman, saying “We are looking forward to her decades of experience, knowledge and leadership being applied to advocating for a stronger Pharmaceutical Benefits Scheme with faster patient access to medicines, and to strengthening Australia’s life sciences sector.

“With the need to get moving with Health Technology Assessment (HTA) reform, the ongoing work to implement our Strategic Agreement with the Government, and our work to ensure Australia’s competitiveness as a destination for clinical trials remains, we look forward to Ms MacLeman’s stewardship at this crucial time for our industry.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.